Researchers presented two reports on the use of beta-blockers in patients with chronic severe mitral regurgitation, or MR, and congestive heart failure, CHF, at the American College of Cardiology's 54th Annual Scientific Session on March 7. These patients had a normal ejection fraction, a measure of how well the heart pumps out blood.
"Our findings are encouraging because there are no data on the survival benefit of medical therapy in CHF or severe MR patients with normal ejection fraction. CHF with normal ejection fraction, popularly referred to as diastolic heart failure, makes up nearly 50 percent of all CHF patients-and these patients have very similar mortality and morbidity as those with reduced ejection fraction," says Padmini Varadarajan, M.D., advanced cardiac imaging fellow in the Department of Cardiovascular Medicine at the Keck School of Medicine and the study's lead author.
In their first presentation, researchers showed that using beta-blockers as part of therapy significantly reduced risk of death for patients with chronic severe mitral regurgitation with normal ejection fraction.
The mitral valve separates the heart's left atrium from the left ventricle. With every heartbeat, oxygen-rich blood moves from the left atrium, a holding chamber, to the left ventricle, which squeezes or ejects the blood out to the rest of the body.
When the mitral valve does not close well, blood can flow from the ventricle back into the atrium-a condition called mitral regurgitation. That means blood flow to the rest of the body decreases, and the heart may have to work extra hard to compensate.
Contact: Sarah Huoh
University of Southern California